Table 3.
Blood pressure and vascular function measurements following 1 week of AME or placebo supplementationa
| Vascular function | AME | Placebo | Intervention effectb | ||
|---|---|---|---|---|---|
| Baseline | After 1 week | Baseline | After 1 week | ||
| Blood Pressure | |||||
| SBP (mmHg) | 106 ± 11 | 105 ± 10 | 107 ± 10 | 106 ± 10 | 0 [– 3, 3]; p = 0.999 |
| DBP (mmHg) | 67 ± 6 | 67 ± 6 | 68 ± 7 | 67 ± 7 | 0 [– 2, 2]; p = 0.753 |
| Heart rate (bpm) | 62 ± 9 | 63 ± 9 | 62 ± 9 | 62 ± 11 | 1 [– 1.8, 3.3]; p = 0.552 |
| MAP (mmHg) | 81 ± 8 | 81 ± 8 | 82 ± 7 | 81 ± 8 | 0 [– 2, 2]; p = 0.881 |
| Arterial Stiffness | |||||
| cAIxHR75 (%) | – 1.3 ± 10.7 | – 3.0 ± 8.8 | – 2.4 ± 15 | – 2.3 ± 10 | – 1.7 [– 4.3, 0.8]; p = 0.173 |
| cfPWV (m/s) | 7.5 ± 1.0 | 7.5 ± 1.0 | 7.6 ± 1.1 | 7.4 ± 0.9 | 0.1 [– 0.3, 0.4]; p = 0.768 |
| Retinal Microvascular Calibers | |||||
| CRAE (μM) | 125 ± 21 | 125 ± 21 | 124 ± 21 | 123 ± 22 | 0 [– 2, 2]; p = 0.758 |
| CRVE (μM) | 218 ± 15 | 218 ± 14 | 219 ± 14 | 218 ± 14 | 0 [– 2, 2]; p = 0.957 |
| AVR | 0.57 ± 0.09 | 0.57 ± 0.10 | 0.57 ± 0.09 | 0.57 ± 0.10 | 0.00 [– 0.01, 0.01]; p = 0.746 |
AVR arteriolar-to-venular-ratio, cAIxHR75 central augmentation index adjusted for heart rate, CRAE central retinal arteriolar equivalent, CRVE central retinal venular equivalent, DBP diastolic blood pressure, MAP mean arterial pressure, cfPWV carotid-to-femoral pulse wave velocity, SBP systolic blood pressure
aData are presented as means ± SDs
bAnalysis was performed with a linear mixed model using intervention, period, and sex as fixed factors, and baseline values as covariate